Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of STRIDE (Durvalumab + Tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC)

NCT06880523 is registered in ClinicalTrials.gov with Canadian Cancer Trials Group as lead sponsor.

NCT NCT06880523
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06880523 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of STRIDE (Durvalumab + Tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
Lead sponsor
Canadian Cancer Trials Group
Phase
Phase 2
Overall status
Recruiting
Start date
October 21, 2025
Completion date
December 31, 2028
Enrollment
140 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma